Pimavanserin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Parkinson Disease Psychosis

Conditions

Parkinson Disease Psychosis

Trial Timeline

Feb 10, 2020 → Apr 26, 2022

NCT ID

NCT04292223

About Pimavanserin

Pimavanserin is a approved stage product being developed by Acadia Pharmaceuticals for Parkinson Disease Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04292223. Target conditions include Parkinson Disease Psychosis.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson Disease Psychosis were approved

Approved (20) Terminated (3) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Lemborexant + placeboEisaiApproved

✅Safinamide MesilateEisaiApproved

✅Istradefylline PillKyowa KirinApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05796167	Phase 1	Withdrawn	Jan 27, 2023	Jun 24, 2024	Parkinson Disease
NCT05357612	Approved	Recruiting	Jan 23, 2023	Aug 1, 2026	Neurodegenerative Diseases
NCT04809116	Approved	Withdrawn	Dec 15, 2022	Dec 15, 2023	Insomnia Chronic
NCT05555615	Phase 2/3	Terminated	Nov 2, 2022	Feb 14, 2025	Irritability Associated With Autism Spectrum Disorder
NCT04292223	Approved	Completed	Feb 10, 2020	Apr 26, 2022	Parkinson Disease Psychosis
NCT04000009	Phase 3	Terminated	Jun 6, 2019	Feb 22, 2021	Adjunctive Treatment of Major Depressive Disorder
NCT03623321	Phase 3	Completed	Jul 17, 2018	May 5, 2023	Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NCT03482882	Phase 2	Completed	Mar 9, 2018	Jul 24, 2019	Treatment of Depression in Adults With Parkinson's Disease (PD)
NCT03118947	Phase 2	Completed	Feb 23, 2017	Feb 25, 2019	Agitation and Aggression in Alzheimer's Disease
NCT03121586	Phase 3	Terminated	Jan 1, 2017	May 30, 2024	Schizophrenia
NCT03018340	Phase 2	Completed	Dec 1, 2016	Oct 1, 2018	Adjunctive Treatment of Major Depressive Disorder

Competing Products

20 competing products in Parkinson Disease Psychosis

See all competitors

Product	Company	Stage	Hype Score
exidavnemab + Placebo Comparator	BioArctic AB	Phase 2	36
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
LY4006896 + Placebo	Eli Lilly	Phase 1	36
ATH-1017 + Placebo	LeonaBio	Phase 2	17
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
Mirabegron + Placebo	Astellas Pharma	Approved	43
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
Equfina 50 mg	Eisai	Pre-clinical	26
Equfina	Eisai	Pre-clinical	26
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
Safinamide Mesilate	Eisai	Approved	43
E2007 + E2007 + E2007	Eisai	Phase 2	35